Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 451 - 475 of 14518 in total
Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert–Eaton myasthenic syndrome (LEMS), has been investigated...
Approved
Investigational
Matched Description: … subsequently prolongs the action potential and increases presynaptic calcium concentrations [A33863] ... diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and ... It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally …
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many...
Approved
Investigational
Matched Description: … such as STAT3, PI3K/ATK, and RAS/MAPK. ... [A199122] Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known ... tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.
Approved
Investigational
Matched Description: … Diabetes, Ocular Physiology, and Regional Blood Flow. ... Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Abametapir is a novel pediculicidal metalloproteinase inhibitor used to treat infestations of head lice. The life cycle of head lice (Pediculus capitis) is approximately 30 days, seven to twelve of which are spent as eggs laid on hair shafts near the scalp. Topical pediculicides generally lack adequate ovicidal activity, including...
Approved
Investigational
Matched Description: … agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas. ... The necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to ... lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is...
Approved
Investigational
Matched Description: … produce a broad adaptative and innate immune cell inhibitory activity. ... Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases ... [A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942]...
Approved
Investigational
Matched Description: … , and serotonin. ... [A252947] The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein ... A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Approved
Investigational
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.
Approved
Matched Description: … Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. …
Matched Categories: … ACE Inhibitors and Diuretics ... zofenopril and diuretics ... Amino Acids, Peptides, and Proteins …
Approved
Matched Categories: … Salicylic Acid and Derivatives …
Fluorodopa F 18 is a fluorinated analog of levodopa used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes. Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily to visualize dopaminergic nerve terminals in the striatum.
Approved
Experimental
Matched Description: … [L12849] Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells,...
Approved
Investigational
Matched Description: … and mantle cell lymphoma. ... Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma ... ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] Sumatriptan was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan. Triptans...
Approved
Investigational
Matched Description: … It is currently available in both tablet and nasal spray forms.[L12978] ... A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and ... [A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
Approved
Matched Description: … It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Approved
Matched Categories: … Adrenergic and Dopaminergic Agents …
Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Approved
Matched Description: … Rizatriptan is a second-generation triptan [A258918] and a selective 5-HT1B and 5-HT1D receptor ... [L46018] Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual,...
Approved
Investigational
Vet approved
Matched Description: … It may slow progression of the clinical disease and delay the requirement for levodopa therapy. …
An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia,...
Approved
Investigational
Vet approved
Matched Description: … An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough ... 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and
Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.
Approved
Nalmefene, a 6-methylene analogue of naltrexone, is an opioid receptor antagonist. It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. In Europe, nalmefene oral tablets are used to reduce alcohol consumption in adults with alcohol dependence. Nalmefene...
Approved
Investigational
Withdrawn
Matched Description: … [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist …
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning...
Approved
Matched Description: … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for ... The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and
Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . Hepatitis C is an infectious liver disease...
Approved
Investigational
Matched Description: … daclatasvir and [DB08934] therapy were 88% and 99%, respectively [FDA Label]. ... Daclatasvir is shown to target both the cis- and trans-acting functions of NS5A and disrupts the function ... M28 in genotype 1a patients and Y93H in genotype 3 patients. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... daclatasvir, asunaprevir and beclabuvir …
Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and...
Approved
Investigational
Matched Description: … female patients 12 years and older. ... FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and ... cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers...
Approved
Matched Description: … treatment for these types of cancers as patients generally have better survival, side effect profiles, and
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists ... Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists …
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Approved
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a...
Approved
Investigational
Matched Description: … The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and ... [L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic ... The dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 451 - 475 of 14518 in total